| The viability of DNA vaccines--marcus evans conference. 3-5 February 2004, London, UK. | |
| | |
MedLine Citation:
|
PMID: 15017462 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
This DNA vaccines conference was aimed at examining the viability of DNA vaccines as a credible prophylactic/therapeutic technology rather than simply as an effective research tool. Presentations and panel discussion sessions focused on many of the issues facing the sector, including efficacy, manufacturing costs and public acceptability of the technology. Clinical trial data were presented for DNA vaccines in development for both human and veterinary use, including cancer, HIV infection and malaria. Presentations also covered delivery technologies (microparticles, electroporation and epidermal 'tattooing'), and the manufacturing industry reported on the latest production advances. Issues concerning human vaccine development are covered in this review. |
| | |
Authors:
|
John B March |
Publication Detail:
|
Type: Congresses |
Journal Detail:
|
Title: IDrugs : the investigational drugs journal Volume: 7 ISSN: 1369-7056 ISO Abbreviation: IDrugs Publication Date: 2004 Mar |
Date Detail:
|
Created Date: 2004-03-12 Completed Date: 2004-07-06 Revised Date: 2004-11-17 |
Medline Journal Info:
|
Nlm Unique ID: 100883655 Medline TA: IDrugs Country: England |
Other Details:
|
Languages: eng Pagination: 226-8 Citation Subset: IM |
Affiliation:
|
Moredun Research Institute, Department of Bacteriology, Penicuik, Edinburgh, EH26 0PZ, UK. John.March@mri.sari.ac.uk |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Drug Delivery Systems / methods* HIV Infections / drug therapy, genetics Humans Malaria / drug therapy, genetics Neoplasms / drug therapy, genetics Vaccines, DNA / administration & dosage*, genetics |
| Chemical | |
Reg. No./Substance:
|
0/Vaccines, DNA |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Signal Transduction Pathways as Therapeutic Targets. 25-28 January 2004, Luxembourg.
Next Document: Longitudinal changes in plasma glucose values of the 75-g glucose tolerance test in triplet pregnanc...